CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹5,484 Cr | ₹5,246 Cr | ₹5,033 Cr | ₹4,913 Cr | ₹4,591 Cr |
What is the latest Total Current Liabilities ratio of CIPLA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹5,484 Cr |
| Mar2024 | ₹5,246 Cr |
| Mar2023 | ₹5,033 Cr |
| Mar2022 | ₹4,913 Cr |
| Mar2021 | ₹4,591 Cr |
How is Total Current Liabilities of CIPLA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹5,484 Cr | 4.54 | |
| Mar2024 | ₹5,246 Cr | 4.22 | |
| Mar2023 | ₹5,033 Cr | 2.45 | |
| Mar2022 | ₹4,913 Cr | 7.01 | |
| Mar2021 | ₹4,591 Cr | - | |
Compare Total Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹123,254.1 Cr | 1.4% | -2.4% | -3.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹416,477.0 Cr | 2.5% | 4% | -3.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹174,934.0 Cr | -1% | 0.5% | 9.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹129,469.0 Cr | 6.9% | 8.7% | 21% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,038.0 Cr | 2.4% | -2.2% | -4.5% | Stock Analytics | |
| MANKIND PHARMA | ₹93,120.4 Cr | -0.3% | -7.6% | -16.6% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 1.4% |
-2.4% |
-3.4% |
| SENSEX | 1.4% |
2.4% |
5.1% |
You may also like the below Video Courses